The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China

• DOI: 10.3389/fonc.2022.1084683
• Publication Date: 2022-12-20T07:55:11Z
• Authors: Qingxiao Chen; Xiaoyan Han; Gaofeng Zheng; Yang Yang; Yi Li; Enfan Zhang; Li Yang; Mengmeng Dong; Donghua He; Jingsong He; Zhen Cai
• Keywords: Single Center; Center (category theory)

Multiple myeloma is genetically heterogeneous, and chromosome abnormalities play a pivotal role in prognosis. A gain 1q (+1q) among the most common cytogenetic abnormalities; however, its relationship with overall survival (OS) progression-free (PFS) patients multiple still unclear. We aim to clarify impact of +1q on clinical characteristics outcomes treated bortezomib-based combination regimes. retrospectively analyzed 258 first diagnosed who underwent therapy at bone marrow transplantation department treatment center affiliated hospital Zhejiang University, China. identified newly our from July 2013 September 2018. observed that 127 (49.2%) acquired diagnosis, strongly correlated occurrence del(13q) IgH rearrangement (P < 0.001). In +1q, PFS was 22.2 months (95% CI 15.8-28.5 months), three-year five-year 35.1% 15.3%, respectively. Univariate analysis revealed albumin, lactate dehydrogenase (LDH), percentage plasma cells significantly affected PFS. Multivariate showed LDH patients. terms OS, median OS for 47.4 34.7-59.5), while non-+1q not reached = 0.048). The univariate multivariate analyses age, platelet count, extramedullary lesions were significant adverse factors There no statistical differences between when there other chromosomal abnormalities, but decreased tendency also had synergistic effect survival. associated higher tumor burden diagnosis. era novel agents, affects OS.